AdipoPharma SAS is developing a therapeutic peptide, PATAS, that targets adipocyte cells to restore healthy lipid biosynthesis and reduce harmful lipids like ceramides, which contribute to insulin resistance and type 2 diabetes. This approach aims to improve metabolic health by addressing the underlying lipid management issues associated with these conditions, with clinical trials set to begin in 2025.
Funding
$34.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 2 diabetes and related metabolic disorders are characterized by insulin resistance and dysfunctional lipid metabolism. Current treatments often fail to address the underlying issues of unhealthy lipid biosynthesis and the accumulation of harmful lipids like ceramides in adipocytes.
Solution
AdipoPharma is developing PATAS, a therapeutic peptide designed to target adipocytes and restore healthy lipid biosynthesis. By modulating lipid homeostasis within these cells, PATAS aims to reduce the levels of detrimental lipids such as ceramides, which contribute to insulin resistance and associated complications. This targeted approach seeks to improve overall metabolic health by directly addressing the dysfunctional lipid management inherent in type 2 diabetes, liver steatosis and fibrosis, and cardiovascular dysfunction. Clinical trials are planned to evaluate PATAS's efficacy in improving insulin sensitivity, reducing beta cell plaque, and mitigating liver and cardiovascular complications.
Target Audience
The primary target audience includes individuals with type 2 diabetes, insulin resistance, and associated metabolic comorbidities, as well as clinicians specializing in endocrinology and metabolic disorders.
Features
- First-in-class "Adipeutic" drug targeting adipocyte function
- Designed to restore healthy lipid biosynthesis within adipocytes
- Reduces levels of ceramides and other harmful lipids
- Aims to improve insulin resistance and beta cell function
- Potential to mitigate liver steatosis and fibrosis
- May reduce the risk of cardiovascular dysfunction associated with diabetes